Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine injection in myelodysplastic syndromes (single-arm, Phase III, China)
CTR20160080Phase 3Active
- Sponsor
- Hangzhou Rongli Pharmaceutical Technology
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Hangzhou Rongli Pharmaceutical Technology. Started Mar 2016; status: active.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20160080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160080.